PBYI - NASDAQ

Puma Biotechnology, Inc.

PBYI·NASDAQ

$6.83

-2.2%

HealthcareBiotechnology

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for the use of neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer; PB272 (neratinib, oral) for HER2 mutation-positive solid tumors. It has a license agreement with Pfizer, Inc.; and sub-license agreement with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$347.53M

EPS0.6200

P/E Ratio11.01

Earnings Date08/06/2026

216.30M

Assets

3Y-3.0%

5Y-11.0%

10Y-14.0%

85.96M

Total Liabilities

-29%

3Y-57.0%

5Y-66.0%

10Y+100.0%

130.34M

Total Equity

41%

3Y+503.0%

5Y-2290.0%

10Y-38.0%

Puma Biotechnology, Inc. Funding & Solvency Profile

PBYI · NASDAQ

Current Assets

Cash & Cash Equivalents29.64M

Net Receivables53.65M

Inventory5.51M

Other Current Assets5.99M

Total Current Assets163 M

Non-Current Assets

Property, Plant & Equipment5.56M

Goodwill & Intangible Assets41.39M

Long-Term Investments0.00

Other Non-Current Assets2.83M

Total Non-Current Assets8 M

Total Assets

216.30M

Financial Health Analysis

Current Ratio

2.00x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

0.66x

Balanced capital structure with moderate leverage. Equity exceeds debt, suggesting healthy financial stability.

Working Capital

81 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

75% Current

Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.

Financial Health Insight

Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.

Puma Biotechnology, Inc. Balance Sheet

PBYI • NASDAQ

Puma Biotechnology, Inc. Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017	Dec 2016	Dec 2015	Dec 2014	Dec 2013	Dec 2012	Dec 2011	Dec 2010	Dec 2009	Dec 2008	Dec 2007
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	29.6M	69.2M	84.6M	76.2M	63.1M	85.3M	60M	108.4M	81.7M	194.5M	31.6M	38.5M	43M	137.4M	53.4M	462.0	2.4K	73.0	1.4M
Short-Term Investments	67.9M	31.7M	11.4M	4.9M	19M	8.1M	51.6M	57M	0.0	35M	184.3M	102.8M	40.9M	0.0	0.0	0.0	0.0	0.0	0.0
Cash & Short-Term Investments	97.5M	101M	95.9M	81.1M	82.1M	93.4M	60M	108.4M	81.7M	194.5M	31.6M	38.5M	83.9M	137.4M	53.4M	462.0	2.4K	73.0	1.4M
Net Receivables	53.7M	32M	48.5M	42.3M	32.5M	25.5M	28.9M	21.9M	9.7M	0.0	0.0	1.8M	9.8M	10.6M	0.0	0.0	0.0	0.0	0.0
Accounts Receivables	53.7M	32M	47.8M	40.4M	32.5M	25.5M	28.9M	20.8M	9.7M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other Receivables	0.0	0.0	652K	1.9M	0.0	0.0	0.0	1.2M	0.0	0.0	0.0	1.8M	9.8M	10.6M	0.0	0.0	0.0	0.0	0.0
Inventory	5.5M	8.7M	7.1M	4.5M	7.1M	3.5M	3.2M	2.6M	2M	0.0	0.0	102.8M	0.0	8K	0.0	0.0	0.0	0.0	0.0
Prepaids	0.0	2.3M	4.4M	4.5M	6.8M	12M	13.3M	9.2M	1.3M	1.2M	1.1M	1M	554K	952K	281K	0.0	0.0	0.0	0.0
Other Current Assets	6M	3.7M	260K	2M	11.4M	11.8M	61M	3.9M	11.7M	0.0	0.0	5.3M	2.1M	0.0	281.1K	0.0	0.0	0.0	0.0
Total Current Assets	162.7M	147.7M	156.2M	134.3M	140M	146.1M	166.3M	203M	106.4M	236.5M	223.5M	149.4M	96.4M	149M	53.7M	462.0	2.4K	73.0	1.4M
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	5.6M	5.1M	8.6M	12.5M	15.8M	18.9M	21.8M	4M	4.5M	5.2M	2.4M	2.2M	1.7M	1.5M	682.1K	0.0	0.0	0.0	0.0
Intangible Assets	41.4M	51.1M	60.9M	70.6M	66.1M	74.1M	40.5M	44.4M	48.4M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Goodwill & Intangible Assets	41.4M	51.1M	60.9M	70.6M	66.1M	74.1M	40.5M	44.4M	48.4M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Long-Term Investments	0.0	0.0	2.1M	0.0	0.0	0.0	4.3M	2K	4.3M	4.3M	4.3M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Tax Assets	3.8M	7.1M	0.0	0.0	0.0	0.0	-4.3M	1.7M	-4.3M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other Non-Current Assets	2.8M	2.4M	2.7M	4.7M	4.7M	5.1M	6.3M	6M	6.3M	6.8M	9.6M	11.2M	6.3M	1.2M	1.1M	0.0	0.0	0.0	0.0
Total Non-Current Assets	53.6M	65.7M	74.3M	87.8M	86.6M	98.1M	68.6M	56.1M	59.1M	16.3M	16.3M	13.4M	8M	2.7M	1.7M	0.0	0.0	0.0	0.0
Total Assets	216.3M	213.3M	230.5M	222.1M	226.6M	244.2M	234.9M	259.1M	165.5M	252.8M	239.8M	162.8M	104.4M	151.7M	55.4M	462.0	2.4K	73.0	1.4M
LIABILITIES
CURRENT LIABILITIES
Total Payables	5.1M	5.5M	6.9M	6.4M	11.2M	12.1M	19.2M	20.7M	27.7M	20M	17.8M	15M	10.7M	482K	86.7K	0.0	2.3K	2.2K	0.0
Accounts Payable	5.1M	5.5M	6.9M	6.4M	11.2M	12.1M	19.2M	20.7M	27.7M	20M	17.8M	15M	10.7M	482K	86.7K	0.0	2.3K	2.2K	0.0
Accrued Expenses	0.0	0.0	10.3M	53.6M	83.6M	69.7M	29.7M	6.1M	2.8M	17.4M	14.6M	18.9M	8.6M	787K	308.9K	0.0	0.0	0.0	0.0
Short Term Debt	23.8M	45.3M	34M	0.0	0.0	14.3M	2.6M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Capital Lease Obligations (Current)	0.0	5.5M	4.8M	4.1M	3.6M	3.1M	2.6M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Tax Payables	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	16.4M	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other Current Liabilities	52.4M	39.7M	43.4M	13.3M	11.2M	15.1M	36.7M	40.3M	27.9M	0.0	0.0	10.6M	0.0	20.4M	190.6K	0.0	0.0	0.0	0.0
Total Current Liabilities	81.3M	96.1M	99.4M	77.5M	109.6M	114.3M	90.8M	67.1M	58.3M	37.5M	32.4M	44.4M	19.3M	21.7M	586.2K	0.0	2.3K	2.2K	0.0
NON-CURRENT LIABILITIES
Long Term Debt	4.7M	21.7M	65.7M	98.3M	97.1M	84M	95M	151.9M	48.5M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other Non-Current Liabilities	0.0	1.9M	5M	12.8M	6.4M	32.3M	9M	5.8M	5.4M	5.5M	1.4M	1.3M	1.1M	1.1M	439.4K	0.0	0.0	0.0	0.0
Total Non-Current Liabilities	4.7M	25.1M	77.7M	123M	119.4M	135.9M	126.6M	157.7M	53.9M	5.5M	1.4M	1.3M	1.1M	1.1M	439.4K	0.0	0.0	0.0	0.0
Other Liabilities	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.4M
Capital Lease Obligations	0.0	7M	11.8M	16M	19.5M	22.6M	25.3M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total Liabilities	86M	121.2M	177.1M	200.5M	229M	250.2M	217.4M	224.8M	112.2M	43M	33.8M	45.7M	20.4M	22.8M	1M	0.0	2.3K	2.2K	1.4M
SHAREHOLDERS' EQUITY
Preferred Stock	0.0	0.0	0.0	0.0	0.0	0.0	37K	0.0	449K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Common Stock	5K	5K	5K	5K	4K	4K	4K	4K	4K	4K	3K	3K	3K	3K	2K	300.0	300.0	300.0	300K
Additional Paid-In Capital	0.0	1.4B	1.4B	1.4B	1.4B	1.3B	1.3B	1.2B	1.1B	1B	726.7M	399.2M	223.2M	213.5M	64.6M	62.2K	45.9K	26.7K	0.0
Retained Earnings	-1.3B	-1.3B	-1.3B	-1.4B	-1.4B	-1.3B	-1.3B	-1.2B	-1.1B	-796.5M	-520.5M	-281.2M	-139.3M	-84.6M	-10.2M	-62K	-46K	-29.2K	0.0
Accumulated Other Comprehensive Income/Loss	36K	6K	-4K	0.0	-2K	0.0	62K	-12K	-449K	-13K	-147K	-95K	3K	-276K	-10.7K	0.0	0.0	0.0	0.0
Other Total Stockholders' Equity	1.4B	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-835K	0.0	-9K	11K	0.0	0.0	0.0	1.1M
Total Stockholders' Equity	130.3M	92.1M	53.4M	21.6M	-2.4M	-6M	17.5M	34.3M	53.3M	209.8M	206M	117M	84M	128.9M	54.4M	462.0	138.0	-2.2K	1.4M
Total Equity	130.3M	92.1M	53.4M	21.6M	-2.4M	-6M	17.5M	34.3M	53.3M	209.8M	206M	117M	84M	128.9M	54.4M	462.0	138.0	-2.2K	1.4M
SUMMARY
Total Liabilities & Equity	216.3M	213.3M	230.5M	222.1M	226.6M	244.2M	234.9M	259.1M	165.5M	252.8M	239.8M	162.7M	104.4M	151.7M	55.4M	462.0	2.4K	73.0	1.4M
Total Investments	67.9M	31.7M	13.4M	4.9M	19M	8.1M	51.6M	57M	4.3M	35M	184.3M	102.8M	40.9M	0.0	0.0	0.0	0.0	0.0	0.0
Total Debt	28.5M	74.1M	111.5M	114.3M	116.6M	121M	120.2M	151.9M	48.5M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net Debt	-1.1M	4.9M	26.9M	38.1M	53.5M	35.7M	60.2M	43.5M	-33.2M	-194.5M	-31.6M	-38.5M	-43M	-137.4M	-53.4M	-462.0	-2.4K	-73.0	-1.4M
Shares Outstanding	50,370,723	50,370,723	50,370,723	50,370,723	50,370,723	50,370,723	50,370,723	50,370,723	50,370,723	50,370,723	50,370,723	50,370,723	50,370,723	50,370,723	50,370,723	50,370,723	50,370,723	50,370,723	50,370,723

SEC Filings

PBYI - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
10-Q 10-Q 2026 Q1 Q1	May 07, 2026	March 31, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 07, 2026	May 07, 2026	2026	View Filing
DEF 14A DEF 14A 2026 N/A	April 28, 2026	June 11, 2026	2026	View Filing
10-K 10-K 2025 FY FY	February 26, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	February 26, 2026	February 26, 2026	2026	View Filing
10-Q 10-Q 2025 Q3 Q3	November 06, 2025	September 30, 2025	2025	View Filing
8-K 8-K 2025 N/A	November 06, 2025	November 06, 2025	2025	View Filing
8-K 8-K 2025 N/A	August 07, 2025	August 07, 2025	2025	View Filing
10-Q/A 10-Q/A 2025 Q1 (Amended) Q1	August 07, 2025	March 31, 2025	2025	View Filing
10-Q 10-Q 2025 Q2 Q2	August 07, 2025	June 30, 2025	2025	View Filing

Showing 1 to 10 of 305 filings

Related Guides

Blog Categories

Continue your PBYI research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.